Created in 1983 under the auspices of the Fondation de France, the Fondation IPSEN tracks progress in biomedical research with the continuing aim of highlighting fundamental advances. Staying away from passing trends, the ambition of the Fondation IPSEN is to identify emerging knowledge and new paradigms and to foster the most promising interconnections between domains that have not previously been communicating. Because it was necessary to concentrate its efforts, the topics selected reflect some of the most important challenges for the current evolution of the world as well as of knowledge: the aging of populations; the spectacular development of neuroscience and its contribution to the understanding of cognitive mechanisms; the interactions between the great biological systems, such as the nervous and endocrine systems, and the medical challenges posed by the biomedical revolution, particularly in the science of cancer. Over the last 30 years, the Fondation IPSEN has organized over 250 meetings and produced several hundreds publications; more than 250 scientists and biomedical researchers have been awarded prizes and research grants.
Chief Medical Officer
Ipsen Pharma, acting Fondation IPSEN Chairman
Director of Operations
The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science (www.sciencemag.org) as well as Science Translational Medicine (www.sciencetranslationalmedicine.org), Science Signaling (www. sciencesignaling.org), and Science Advances (http://advances.sciencemag.org/). AAAS was founded in 1848, and includes some 261 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world, with an estimated total readership of 1 million.
The non-profit AAAS (www.aaas.org) is open to all and fulfills its mission to “advance science and serve society” not only by publishing the very best scientific research but also through initiatives in science policy, international programs and science education.
Science Translational Medicine was launched in October 2009. The goal of Science Translational Medicine is to promote human health by providing a forum for communicating the latest biomedical research findings from basic, translational, and clinical researchers from all established and emerging disciplines relevant to medicine.
Despite 50 years of advances in our fundamental understanding of human biology and the emergence of powerful new technologies, the translation of this knowledge into effective new treatments and health measures has been slow. This paradox illustrates the daunting complexity of the challenges faced by translational researchers as they apply the basic discoveries and experimental approaches of modern science to the alleviation of human suffering. A major goal of Science Translational Medicine is to publish papers that identify and fill the scientific knowledge gaps at the junction of basic research and medical application in order to accelerate the translation of scientific knowledge into new methods for preventing, diagnosing and treating human disease.
AAAS/ Science Translational Medicine
Deputy Editor, Research
The Institute of Molecular and Cell Biology (IMCB) was launched on 23 January 1985, with the official opening ceremony held on 2 October 1987 at the National University of Singapore (NUS), to develop and support the biomedical R&D capabilities in Singapore. It subsequently became an autonomous research institute (RI) of the Agency for Science, Technology and Research (A*STAR), moving to Biopolis in 2004.
IMCB’s original vision was to foster a vibrant research culture to enable cutting edge discoveries and nurture high-quality talent. The creation and development of IMCB has catalyzed the transformation of Singapore into an international hub for biomedical research, development & innovation by:
1. fostering the biomedical research culture in Singapore
2. placing Singapore onto global map of scientific excellence
3. training & recruiting capable people at all levels
4. facilitating the development of other research entities
Over the years, IMCB has:
1. trained more than 250 PhDs
2. recruited more than 800 PhDs from the international community
3. published over 2,500 research papers in top international peer-reviewed journals, with a yearly citation above 8,000 since 2012
4. established numerous collaborations with industrial, clinical & academic partners, both locally and internationally
Our mission is to:
1. conduct cutting-edge discovery research in disease pathways
2. groom early career researchers to be future leaders in their fields
3. collaborate with medical & industry communities for research impact
IMCB’s Discovery research comprises 5 major programmes:
1. Cancer Cell Signalling
2. Epigenetics and Diseases
3. iPS cell and Regenerative Medicine
4. Multi-Modal Molecular (M3) Biology
5. Technology and Translation
Professor and Executive Director
Esther Meimei LUO